#masimo

[pinkstrawberryeagle]

[paradoxandleather]

He is masterpiece

[macdailynews]

Apple defeats Masimo bid for new Apple Watch import ban at US ITC tribunal

A U.S. trade tribunal ruled in favor of Apple on Friday, rejecting medtech company Masimo’s bid to reinstate an import ban on the Apple Watch. The U.S. International Trade Commission closed Masimo’s case after declining to review a preliminary ruling issued in March by an ITC judge. That ruling found that Apple’s redesigned watches do not infringe Masimo’s patents related to blood-oxygen sensing…

View On WordPress

[macdailynews]

Apple fends off renewed Apple Watch import ban attempt

In a significant development for Apple and its popular Apple Watch wearable lineup, a U.S. International Trade Commission (ITC) administrative law judge has issued a preliminary ruling that the company’s redesigned Apple Watch models do not infringe on patents held by medical technology firm Masimo Corporation. The decision rejects Masimo’s latest attempt to impose a renewed import ban on the…

View On WordPress

[innonurse]

Danaher announces $9.9 billion acquisition of Masimo

- By InnoNurse Staff -

Danaher Corporation announced on Feb. 17, 2026, that it has agreed to acquire Masimo Corporation, a manufacturer of pulse oximetry and patient monitoring technologies used primarily in acute care settings.

Under the terms of the agreement, Danaher will purchase all outstanding Masimo shares for $180 per share in cash, representing a total enterprise value of about $9.9 billion, including debt and net of acquired cash. The deal values Masimo at roughly 18 times its estimated 2027 EBITDA, or about 15 times EBITDA when expected synergies are included.

After the transaction closes, Masimo will operate as a standalone company within Danaher’s Diagnostics segment, alongside businesses such as Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter Diagnostics. Danaher said Masimo’s sensor technologies and AI-enabled monitoring capabilities are expected to strengthen its diagnostics portfolio and expand its reach in patient monitoring.

Danaher expects the acquisition to be accretive to adjusted diluted earnings per share, contributing approximately $0.15–$0.20 in the first full year and about $0.70 by the fifth year after completion. The company also anticipates more than $125 million in annual cost synergies and over $50 million in annual revenue synergies by the fifth year. Masimo is projected to generate more than $530 million in EBITDA by 2027 and deliver high-single-digit core revenue growth over the long term.

The transaction is expected to close in the second half of 2026, subject to regulatory approvals and approval by Masimo shareholders. Danaher plans to finance the acquisition through cash on hand and debt financing.

Read more at Danaher

///

Other recent news and insights

Intellijoint Surgical Inc. and Vena Medical awarded $1.9 million from Ontario’s Life Sciences Scale-Up Fund

AI could help predict your risk of breast cancer in the next four years

New 3D material enables brain cells to communicate

TriZetto data breach: health tech giant reveals personal info of 3.4 million users may have been affected

Open 3D Human Organ Atlas lets users explore anatomy in unprecedented detail

Orchestrated multi-agent AI systems outperform single agents in health care

[macdailynews]

U.S. jury says Apple must pay Masimo $634 million over Apple Watch blood oxygen patent infringement

A federal jury in California ruled on Friday that Apple must pay Masimo, a medical-monitoring technology firm, $634 million in damages for violating a patent on blood-oxygen sensing tech used in the Apple Watch. The verdict upheld Masimo’s claims that features like workout mode and heart rate notifications in the Apple Watch infringed the patent, according to a Masimo spokesperson. Apple has…

View On WordPress

[newstech24]

Jury says Apple owes Masimo $634M for patent infringement

A federal jury in California dominated Friday that Apple should pay medical machine maker Masimo $634 million for infringing a patent on blood oxygen monitoring expertise. Reuters reviews that the jury discovered that the Apple Watch’s exercise mode and coronary heart fee notification options violated Masimo’s patent. “It is a vital win in our ongoing efforts to guard our improvements and mental…

Jury says Apple owes Masimo $634M for patent infringement

[macdailynews]

U.S. ITC scrutinizes redesigned Apple Watch blood oxygen feature

In August 2025, Apple reintroduced a redesigned version of the Blood Oxygen monitoring feature on the Apple Watch in the U.S., shifting data processing from the device to users’ iPhones to circumvent an ongoing patent dispute with health tech firm Masimo. This move came 18 months after Apple began selling certain Apple Watch models without the feature, following a U.S. International Trade…

View On WordPress